These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 9287046)

  • 1. rhIGF-I administration reduces insulin requirements, decreases growth hormone secretion, and improves the lipid profile in adults with IDDM.
    Carroll PV; Umpleby M; Ward GS; Imuere S; Alexander E; Dunger D; Sönksen PH; Russell-Jones DL
    Diabetes; 1997 Sep; 46(9):1453-8. PubMed ID: 9287046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of low-dose recombinant human insulin-like growth factor-I on insulin sensitivity, growth hormone and glucagon levels in young adults with insulin-dependent diabetes mellitus.
    Acerini CL; Harris DA; Matyka KA; Watts AP; Umpleby AM; Russell-Jones DL; Dunger DB
    Metabolism; 1998 Dec; 47(12):1481-9. PubMed ID: 9867078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant human insulin-like growth factor-I (rhIGF-I) therapy in adults with type 1 diabetes mellitus: effects on IGFs, IGF-binding proteins, glucose levels and insulin treatment.
    Carroll PV; Umpleby M; Alexander EL; Egel VA; Callison KV; Sönksen PH; Russell-Jones DL
    Clin Endocrinol (Oxf); 1998 Dec; 49(6):739-46. PubMed ID: 10209561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of recombinant human insulin-like growth factor I on growth hormone secretion in adolescents with insulin dependent diabetes mellitus.
    Cheetham TD; Clayton KL; Taylor AM; Holly J; Matthews DR; Dunger DB
    Clin Endocrinol (Oxf); 1994 Apr; 40(4):515-22. PubMed ID: 8187319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant human insulin-like growth factor-I abolishes changes in insulin requirements consequent upon growth hormone pulsatility in young adults with type I diabetes mellitus.
    Crowne EC; Samra JS; Cheetham T; Watts A; Holly JM; Dunger DB
    Metabolism; 1998 Jan; 47(1):31-8. PubMed ID: 9440474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual hormonal replacement therapy with insulin and recombinant human insulin-like growth factor (IGF)-I in insulin-dependent diabetes mellitus: effects on the growth hormone/IGF/IGF-binding protein system.
    Thrailkill K; Quattrin T; Baker L; Litton J; Dwigun K; Rearson M; Poppenheimer M; Kotlovker D; Giltinan D; Gesundheit N; Martha P
    J Clin Endocrinol Metab; 1997 Apr; 82(4):1181-7. PubMed ID: 9100593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term suppression of elevated growth hormone concentrations following insulin-like growth factor 1 administration in young adults with type 1 diabetes does not alter glomerular filtration or albumin excretion rates.
    Williams RM; Yuen K; White D; Mallard B; Dalton RN; Acerini CL; Dunger DB
    Clin Endocrinol (Oxf); 2006 Oct; 65(4):439-45. PubMed ID: 16984235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship between overnight GH levels and insulin concentrations in adolescents with insulin-dependent diabetes mellitus (IDDM) and the impact of recombinant human insulin-like growth factor I (rhIGF-I).
    Cheetham TD; Connors M; Clayton K; Watts A; Dunger DB
    Clin Endocrinol (Oxf); 1997 Apr; 46(4):415-24. PubMed ID: 9196603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-dependent effects of recombinant human insulin-like growth factor (IGF)-I/IGF binding protein-3 complex on overnight growth hormone secretion and insulin sensitivity in type 1 diabetes.
    Saukkonen T; Amin R; Williams RM; Fox C; Yuen KC; White MA; Umpleby AM; Acerini CL; Dunger DB
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4634-41. PubMed ID: 15356074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of recombinant human insulin-like growth factor I (IGF-I) therapy on the growth hormone-IGF system of a patient with a partial IGF-I gene deletion.
    Camacho-Hübner C; Woods KA; Miraki-Moud F; Hindmarsh PC; Clark AJ; Hansson Y; Johnston A; Baxter RC; Savage MO
    J Clin Endocrinol Metab; 1999 May; 84(5):1611-6. PubMed ID: 10323388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual hormonal replacement with insulin and recombinant human insulin-like growth factor I in IDDM. Effects on glycemic control, IGF-I levels, and safety profile.
    Quattrin T; Thrailkill K; Baker L; Litton J; Dwigun K; Rearson M; Poppenheimer M; Giltinan D; Gesundheit N; Martha P
    Diabetes Care; 1997 Mar; 20(3):374-80. PubMed ID: 9051390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cotherapy with recombinant human insulin-like growth factor I and insulin improves glycemic control in type 1 diabetes. RhIGF-I in IDDM Study Group.
    Thrailkill KM; Quattrin T; Baker L; Kuntze JE; Compton PG; Martha PM
    Diabetes Care; 1999 Apr; 22(4):585-92. PubMed ID: 10189536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recovery of growth hormone release from suppression by exogenous insulin-like growth factor I (IGF-I): evidence for a suppressive action of free rather than bound IGF-I.
    Chapman IM; Hartman ML; Pieper KS; Skiles EH; Pezzoli SS; Hintz RL; Thorner MO
    J Clin Endocrinol Metab; 1998 Aug; 83(8):2836-42. PubMed ID: 9709956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin-like growth factor I and growth hormone (GH) treatment in GH-deficient humans: differential effects on protein, glucose, lipid, and calcium metabolism.
    Mauras N; O'Brien KO; Welch S; Rini A; Helgeson K; Vieira NE; Yergey AL
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1686-94. PubMed ID: 10770216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of recombinant human insulin-like growth factor I administration on the growth hormone (gh) response to GH-releasing hormone in obesity.
    Maccario M; Tassone F; Gianotti L; Lanfranco F; Grottoli S; Arvat E; Muller EE; Ghigo E
    J Clin Endocrinol Metab; 2001 Jan; 86(1):167-71. PubMed ID: 11231996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arginine counteracts the inhibitory effect of recombinant human insulin-like growth factor I on the somatotroph responsiveness to growth hormone-releasing hormone in humans.
    Gianotti L; Maccario M; Lanfranco F; Ramunni J; Di Vito L; Grottoli S; Muller EE; Ghigo E; Arvat E
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3604-8. PubMed ID: 11061509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The combination of insulin-like growth factor I and insulin-like growth factor-binding protein-3 reduces insulin requirements in insulin-dependent type 1 diabetes: evidence for in vivo biological activity.
    Clemmons DR; Moses AC; McKay MJ; Sommer A; Rosen DM; Ruckle J
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1518-24. PubMed ID: 10770191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of recombinant human insulin-like growth factor I administration on growth hormone (GH) secretion, both spontaneous and stimulated by GH-releasing hormone or hexarelin, a peptidyl GH secretagogue, in humans.
    Ghigo E; Gianotti L; Arvat E; Ramunni J; Valetto MR; Broglio F; Rolla M; Cavagnini F; Müller EE
    J Clin Endocrinol Metab; 1999 Jan; 84(1):285-90. PubMed ID: 9920097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of recombinant IGF-I on anterior pituitary function in healthy volunteers.
    Trainer PJ; Holly J; Medbak S; Rees LH; Besser GM
    Clin Endocrinol (Oxf); 1994 Dec; 41(6):801-7. PubMed ID: 7889617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant human insulin-like growth factor-I therapy improves glycemic control and insulin action in the type A syndrome of severe insulin resistance.
    Morrow LA; O'Brien MB; Moller DE; Flier JS; Moses AC
    J Clin Endocrinol Metab; 1994 Jul; 79(1):205-10. PubMed ID: 8027228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.